Digestion · 2006 · 18 citations · 16 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCytotoxic ChemotherapyGastric CancerMalignant NeoplasmsOncology PharmacologyPharmacodynamics Of Anticancer AgentsAnticancer ChemotherapyApoptotic MorphologyChemotherapy-induced ApoptosisCytotoxicity AssaysGastric Cancer PharmacotherapyOxaliplatin-based TherapySurvivin Inhibition
BACKGROUND: The enhanced antitumor effect of paclitaxel when used with oxaliplatin in gastric cancer is reported, however the underlying biological mechanism is unknown. METHODS: We tested the cytotoxic activity, apoptosis, and mitotic catastrophe of paclitaxel and oxaliplatin in MKN-28 and MKN-45 gastric cancer cell lines. The modulation of survivin expression was determined by Western blotting. RESULTS: WST-1 assay indicated that paclitaxel plus oxaliplatin showed better cytotoxicity than paclitaxel alone, even when low concentrations of oxaliplatin were used. Flow cytometry analysis revealed significantly greater increases in apoptotic cells after treatment with paclitaxel followed by low-dose oxaliplatin (1 microM) than after any single-reagent regimen in the MKN-45 cell line. In MKN-28, a difference existed only between combination treatment and oxaliplatin treatment. Morphologic examination showed that the cells undergoing mitotic catastrophe were highest in the combination groups in the both cell lines. Downregulation of survivin expression was found by Western blotting with treatment by paclitaxel, oxaliplatin, or their combination. CONCLUSION: Our findings suggest that the mechanism of enhanced cytotoxicity might be through enhanced mitotic catastrophe and apoptosis, which is possibly due to chemotherapy-induced downregulation of surviving. The combination of paclitaxel and low-dose oxaliplatin should be incorporated into the design of a clinical trial.
16
Control of apoptosis and mitotic spindle checkpoint by survivin
Fengzhi Li, Grazia Ambrosini, Emily Chu et al. · Nature · 1998 · 1.9K citations
Atsushi Ohtsu, Yasuhiro Shimada, Kuniaki Shirao et al. · Journal of Clinical Oncology · 2002 · 431 citations
Medicine, Oncology, Pharmacology +13